7,604.24

+24.17

+0.32%

52,246.36

+476.05

+0.92%

25,513.74

+76.74

+0.30%

2,828.95

+17.11

+0.61%

4.8800

-0.0490

-0.99%

19.76

+0.34

+1.75%

3,964.60

+65.70

+1.69%

77,009.75

-844.24

-1.08%

Crude Oil Dec 26

96.51

-7.61

-7.31%

US Private Equity

10,850.63

-82.20

-0.75%

Canadian Sec - Free Realtime Quote CAD

PharmaTher Holdings Ltd. (PHRM.CN)

0.0500 -0.0050 (-9.09%)

As of 10:03:47 AM EST. Market Open.

Loading Chart for PHRM.CN

Chart Range Bar

Interval:

In partnership with ChartIQ

PharmaTher Builds Portfolio of Personalized, 3D-Printed Peptide Products for New U.S. Peptide Pathway, Led by Colon-Targeted KPV and BPC-157

PharmaTher Builds Portfolio of Personalized, 3D-Printed Peptide Products for New U.S. Peptide Pathway, Led by Colon-Targeted KPV and BPC-157

PharmaTher Launches M3DICINES(TM) National Network Program to Provide 3D-Printed Medicines for Rare Diseases, Discontinued Medicines, Drug Shortages and National Emergencies

PharmaTher Launches M3DICINES(TM) National Network Program to Provide 3D-Printed Medicines for Rare Diseases, Discontinued Medicines, Drug Shortages and National Emergencies

PharmaTher Selects PD Labs, a National 503A Compounding Pharmacy, as the U.S. Center of Excellence for Its Personalized Medicine and Peptide Platform, PERSONALIZ3D(TM)

PharmaTher Selects PD Labs, a National 503A Compounding Pharmacy, as the U.S. Center of Excellence for Its Personalized Medicine and Peptide Platform, PERSONALIZ3D(TM)

PharmaTher Launches New Division to Commercialize Personalized Peptide Products

PharmaTher Launches New Division to Commercialize Personalized Peptide Products

PharmaTher Updates Strategy on Personalized Medicines for Peptides and Psychedelics

PharmaTher Updates Strategy on Personalized Medicines for Peptides and Psychedelics

PharmaTher's Sairiyo Therapeutics to Explore PD-001, Its Patented Reformulated Cepharanthine, for Hantavirus

PharmaTher's Sairiyo Therapeutics to Explore PD-001, Its Patented Reformulated Cepharanthine, for Hantavirus

PharmaDrug Sairiyo Therapeutics to Explore PD-001, Its Patented Reformulated Cepharanthine, for Hantavirus

PharmaDrug Sairiyo Therapeutics to Explore PD-001, Its Patented Reformulated Cepharanthine, for Hantavirus

PharmaTher Highlights Strategic Ketamine Opportunity Following New U.S. Executive Order on Psychedelic Treatments for Serious Mental Illness

PharmaTher Highlights Strategic Ketamine Opportunity Following New U.S. Executive Order on Psychedelic Treatments for Serious Mental Illness

PharmaTher's Microneedle Patch Platforms Positioned to Benefit from Major U.S. Catalysts in Psychedelics and Peptides

PharmaTher's Microneedle Patch Platforms Positioned to Benefit from Major U.S. Catalysts in Psychedelics and Peptides

PharmaTher Supports Proposed U.S. Peptide Reclassification, Reinforcing the Strategic Value of Its Microneedle Patch Platforms for Peptide Delivery

PharmaTher Supports Proposed U.S. Peptide Reclassification, Reinforcing the Strategic Value of Its Microneedle Patch Platforms for Peptide Delivery

PharmaTher Announces Filing of U.S. Patent Application for its Peptide Microneedle Patch Technology

PharmaTher Announces Filing of U.S. Patent Application for its Peptide Microneedle Patch Technology

Mobilize your Website

View Site in Mobile | Classic

Share by: